Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000237969

Medchemexpress LLC (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide | 1233231-30-5 | 98.3% | 419.4 g/mol | C20H20F3N5O2 | 25MG
SDP

Catalog No. 5000237969
Encompass_Preferred

DSP-2230 (ANP-230) is an orally active voltage-gated sodium channel inhibitor used in preclinical research to modulate Nav1.7, Nav1.8, and Nav1.9 activity and to evaluate approaches for neuropathic pain. The compound is supplied as a solid with characterized solubility profiles and storage recommendations for laboratory use only.

  • Inhibits Nav1.7, Nav1.8, and Nav1.9 with reported IC50s of 7.1 μM, 11.4 μM, and 6.7 μM respectively.
  • Reported purity 98.33%.
  • Soluble in DMSO at ≥100 mg/mL; multiple in vivo formulation protocols with solubility ≥2.25 mg/mL are provided.
  • Powder stability: -20°C for up to 3 years; solution stability conditions are reported.
  • Intended for preclinical studies of sodium channel pharmacology and neuropathic pain models.

Catalog No. 50-002-37969 Supplier Medchemexpress LLC Supplier No. HY12507925MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

DSP-2230 (ANP-230) is an orally active voltage-gated sodium channel inhibitor used in preclinical research to modulate Nav1.7, Nav1.8, and Nav1.9 activity and to evaluate approaches for neuropathic pain. The compound is supplied as a solid with characterized solubility profiles and storage recommendations for laboratory use only.

  • Inhibits Nav1.7, Nav1.8, and Nav1.9 with reported IC50s of 7.1 μM, 11.4 μM, and 6.7 μM respectively.
  • Reported purity 98.33%.
  • Soluble in DMSO at ≥100 mg/mL; multiple in vivo formulation protocols with solubility ≥2.25 mg/mL are provided.
  • Powder stability: -20°C for up to 3 years; solution stability conditions are reported.
  • Intended for preclinical studies of sodium channel pharmacology and neuropathic pain models.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.